Firm News: Drugs & Devices: Page 12

Stryker Corp. has agreed to pay potentially more than $1 billion to settle claims from patients injured by the company’s Rejuvenate and ABGII modular hip implants, the nationally prominent personal-injury law firm of Weitz & Luxenberg today announced. The settlement capped nearly four months of intensive negotiations between Stryker and Weitz & Luxenberg’s Ellen Relkin…

On November 3, 2014, a global settlement program involving Stryker’s Rejuvenate and ABGII modular hip implants was executed before and announced by Superior Court Judge Brian R. Martinotti in Bergen County, New Jersey. The settlement was finalized after four months of negotiations before retired United States Magistrate Judge Diane Welsh of JAMS in Philadelphia. Stryker…

Weitz & Luxenberg has launched an investigation of a device that may spread cancer in some surgical patients. Laparoscopic power morcellators, electric tools inserted into the abdomen to remove uterine fibroids and perform hysterectomies, appear to be spreading concealed sarcomas. A set of spinning blades used to cut tissue can accidentally stir up tumor cells,…

Thousands of patients whose hip implants failed and were removed prior to August 31, 2013 and who enrolled in the $2.5 billion settlement will begin to receive their settlement payments. Late last week, DePuy and its parent company Johnson & Johnson agreed to waive its ”walk-away rights” and are proceeding to fund the six-figure settlements…

A Louisiana jury has awarded $9 billion to a New York man who developed bladder cancer after taking Actos. The verdict, issued Monday night, orders Takeda Pharmaceuticals to pay $6 billion in punitive damages, and Eli Lilly to pay $3 billion. Plaintiff Terrence Allen, a New York resident, was diagnosed with bladder cancer in 2011…